1. KD Tripathi MD. Drugs acting on ANS. Essentials of Medical Pharmacology 7th ed. New Delhi, May 2013. Page - 154.
2. Westfall TC, WestfallIn DP. Adrenergic Agonists and Antagonists. Goodman & Gilman’s: The Pharmacological Basis of Therapeutics. 12th ed. New York, New York: McGraw-Hill Medical; 2011. Page - 297.
3. Biaggioni I, Robertson D. Adrenoreceptor Agonists & Sympathomimetic Drugs. Basic and Clinical Pharmacology. 11th ed. New Delhi, India: Tata McGraw Hill Education Private Limited; 2009. Page - 144.
4. Louis B Cantor. Brimonidine in the treatment of glaucoma and ocular hypertension: Therapeutics and clinical risk management. Dec 2006; [Accessed Dec 3, 2020] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1936355/
5. McLaurin, Eugene, Cavet, Megan E, Gomes, Paul J, Ciolino, Joseph B. Brimonidine Ophthalmic Solution 0.025% for Reduction of Ocular Redness: A Randomized Clinical Trial: OVS optometry and vision sciences. March 2018, Vol – 95, Issue -3 [Accessed Dec 3, 2020] https://journals.lww.com/optvissci/fulltext/2018/03000/brimonidine_ophthalmic_solution_0_025__for.13.aspx
6. FDC International Ltd, Electronic Medicines Compendium (EMC); [Revised Oct 2020] [Accessed Dec 3, 2020] https://www.medicines.org.uk/emc/files/pil.3426.pdf
7. Allergan, 1996; U.S. Food & Drug Administration; [Accessed Dec 3, 2020] https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020613s031lbl.pdf